Highlighted Clinical Trials
Period: March 2020 to June 2020
NCT ID: N/A
The epidemiology of patients hospitalized with severe COVID-19 has not been well defined, especially in the American context. There are significant knowledge gaps regarding demographics, clinical characteristics, trajectory of disease, timing of recovery, predictors of organ failure and death, resource utilization, and post-hospital outcomes. In response, the purpose of the RED CORAL study is to inform epidemiology and resource utilization through data collection and creation of a data repository.
The Prevention and Early Treatment of Acute Lung Injury (PETAL) Network is a consortium of academic and affiliated hospitals across the United States, funded by the NHLBI to conduct clinical trials in patients with or at risk for critical illness, including ARDS. Our Network’s goal is to improve outcomes of patients with acute and critical illness through research.
We will identify acute and critically ill patients with COVID-19 and collect detailed data from their hospital stay. We will contribute data to the WHO/ ISARIC COVID registry and to the scientific community in order to advance United States participation in studies of global epidemiology. We will use the data to increase understanding of the clinical course of COVID-19.
RED CORAL will include adult patients with confirmed COVID-19 hospitalized at participating sites who have available clinical data. The study period will include patients who present for admission to study hospitals between March 1 and April 1, 2020.